glp 1 agonist in heart failure GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk Patients With Type 2 Diabetes Efficacy of GLP‐1 receptor agonists

VSMC phenotypic switching is characterized by transformation from a quiescent contractile to an activated synthetic phenotype, promoting proliferation and leading to the formation of the neointima, the pathological vascular compartment critical for the development of atherosclerosis

We then categorized these reactions and analyzed reporting patterns across different therapies

New research unveiled at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM25) in Barcelona has highlighted the complexity that these drugs introduce into metabolic imaging, signaling a need for revised evaluation protocols to avoid diagnostic pitfalls

Because GLP-1 drugs are not opioid-based treatments and are not primarily SUD treatments, they are positioned to completely bypass the culture wars surrounding substance use treatment, which will enable them to have a dramatic impact on the global prevalence of addiction, at a scale that existing treatments cannot reach

Tirzepatide (Zepbound) was not included as that drug was only approved for obesity late in 2023

In your pancreas, GLP-1 stimulates insulin secretion in a glucose-dependent manner